Abeona Therapeutics Inc. (ABEO) P/E Ratio History
ExpensiveTrading at 6.5x vs 5Y avg 4.1x · 86th percentile · Material premium to history · Data 2013–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Abeona Therapeutics Inc. (ABEO) trades at a price-to-earnings ratio of 6.5x, with a stock price of $6.55 and trailing twelve-month earnings per share of $1.17.
The current P/E is 58% above its 5-year average of 4.1x. Over the past five years, ABEO's P/E has ranged from a low of 0.5x to a high of 9.3x, placing the current valuation at the 86th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, ABEO trades at a 72% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, ABEO trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ABEO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ABEO Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ABEO P/E vs Peers
Cell and Gene Therapy Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $11B | 53.9 | -Best | +128%Best | |
| $4B | 11.4Lowest | -Best | +68% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ABEO Historical P/E Data (2013–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $4.48 | $0.95 | 4.7x | +14% |
| FY2025 Q4 | Dec 31 2025 | $5.27 | $1.01 | 5.2x | +26% |
| FY2025 Q3 | - | $5.28 | $1.14 | 4.6x | +12% |
| FY2025 Q2 | Jun 30 2025 | $5.68 | $0.61 | 9.3x | +126% |
| FY2013 Q4 | - | $312.50 | $103.82 | 3.0x | -27% |
| FY2013 Q3 | Sep 30 2013 | $562.50 | $1140.94 | 0.5x | -88% |
| FY2013 Q2 | Jun 30 2013 | $600.00 | $397.69 | 1.5x | -63% |
Average P/E for displayed period: 4.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ABEO — Frequently Asked Questions
Quick answers to the most common questions about buying ABEO stock.
What is ABEO's P/E ratio?
Abeona Therapeutics Inc. (ABEO) trailing twelve-month P/E ratio is 6.5x, based on TTM diluted EPS of $1.17. The 5-year average P/E is 4.1x and the historical range spans 0.5x to 9.3x.
Is ABEO stock overvalued or undervalued?
ABEO trades at 6.5x P/E, above its 5-year average of 4.1x. The 86th percentile ranking within the 0.5x–9.3x historical range indicates a premium to historical valuation.
Is ABEO stock expensive?
Yes, ABEO is expensive relative to its own history. The current P/E of 6.5x is above the 5-year average of 4.1x. The stock sits at the 86th percentile of its 5-year valuation range.
What is ABEO's historical P/E range?
Over the past 5 years, ABEO's P/E ratio has ranged from 0.5x to 9.3x, with a median of 4.6x and an average of 4.1x. The current P/E of 6.5x places the stock at the 86th percentile of this range. Full historical data spans 2013–2026.
How does ABEO's P/E compare to the S&P 500?
ABEO trades at 6.5x P/E versus the S&P 500 median of 25.9x. The 75% discount to the market suggests lower growth expectations or perceived higher risk.
How does ABEO's valuation compare to Healthcare peers?
Abeona Therapeutics Inc. P/E of 6.5x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ABEO's PEG ratio?
ABEO PEG ratio is N/A, based on a P/E of 6.5x and EPS growth of 165.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ABEO's earnings yield?
ABEO earnings yield is 15.42%, the inverse of its 6.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.